current
avail
prognost
tool
inadequ
discern
molecular
basi
heterogen
respons
hepat
c
viru
hcv
infect
patient
treat
current
standard
therapi
express
biolog
function
immun
mediat
shown
critic
phase
immun
respons
hcv
infect
like
therefor
influenc
host
respons
herein
biometr
multiplex
serum
cytokin
assay
util
character
immunomodulatori
effect
host
respons
hcv
patient
serum
level
cytokin
compar
month
treatment
control
overal
serum
cytokin
level
significantli
higher
patient
p
control
addit
viral
titer
decreas
patient
month
therapi
overal
serum
cytokin
level
cohort
p
assess
relationship
chang
cytokin
level
chang
viral
titer
cohort
divid
three
statist
distinct
subgroup
base
chang
viral
titer
specif
set
cytokin
decreas
group
decreas
interleukin
il
correl
greatest
drop
viral
titer
decreas
granulocyt
coloni
stimul
factor
gcsf
correl
moder
drop
viral
titer
correl
lowest
drop
viral
titer
interestingli
decreas
level
correl
decreas
viral
titer
patient
control
leukocyt
influx
thu
propag
inflamm
conclus
data
rais
possibl
characterist
chang
host
respons
modul
therapeut
respons
demonstr
prognost
power
serum
cytokin
profil
chronic
hcv
hepat
c
viru
hcv
infect
worldwid
epidem
among
lead
infecti
caus
morbid
mortal
populationbas
studi
indic
chronic
liver
diseas
hcvrelat
becom
chronic
patient
may
progress
cirrhosi
also
major
risk
factor
develop
hepatocellular
carcinoma
current
therapi
hcv
infect
includ
pegyl
interferon
ifn
plu
ribavirin
sustain
virolog
respons
svr
rate
combin
therapi
improv
compar
less
monotherapi
patient
infect
hcv
genotyp
estim
curabl
rate
approxim
combin
wherea
pegyl
ribavirin
combin
therapi
help
achiev
svr
rate
hcv
relaps
treatment
week
given
clinic
econom
cost
hepat
c
infect
surprisingli
littl
known
regard
molecular
mechan
govern
therapeut
respons
importantli
nonrespons
standard
treatment
evid
elucid
progress
pathogen
portal
inflammatori
process
septal
fibrosi
interfac
hepat
lobular
necroinflammatori
lesion
hepat
c
demonstr
import
host
immun
respons
hcv
pathogen
howev
immunomodulatori
mechan
involv
pathogen
progress
hcvrelat
liver
diseas
poorli
character
due
part
insuffici
evid
lack
suitabl
anim
model
defect
abil
mount
effici
cellular
immun
respons
propos
primarili
induc
establish
chronic
cytokin
critic
phase
immun
respons
hcv
infect
earli
onset
liver
damag
chronic
infect
viral
persist
tissu
damag
fibrosi
immun
respons
hcv
mediat
predominantli
respons
peripheri
respons
liver
elev
serum
level
cytokin
interleukin
il
observ
chronic
hcv
patient
cytokin
produc
cell
play
import
role
inhibit
viral
replic
caus
liver
injuri
macrokin
novel
macrophageregul
agent
shown
downregul
elev
level
tumor
necrosi
factor
tnf
dosedepend
fashion
nonrespons
patient
hcv
infect
cytokin
therefor
play
critic
role
coordin
respons
immun
system
viral
infect
furthermor
control
cytokin
product
highli
complex
multifactori
effect
cytokin
mediat
multipl
regulatori
network
intric
complex
cytokin
network
clearli
conceal
role
singl
cytokin
may
play
pathogenesi
diseas
therefor
inform
investig
immunopathogenesi
diseas
process
analyz
multipl
cytokin
util
broadspectrum
beadbas
multiplex
immunoassay
effect
character
serum
level
cytokin
mediat
humor
cellular
immun
inflamm
correl
serum
cytokin
level
diseas
activ
character
immunomodulatori
effect
therapi
month
posttreat
provid
us
better
understand
role
cellular
humor
chemotact
immun
critic
time
treatment
cours
hcv
infect
signific
chang
viral
titer
observ
studi
popul
studi
popul
consist
adult
patient
men
women
mean
age
ci
chronic
hepat
c
previous
undergon
treatment
combin
pegyl
ribavirin
patient
previous
fail
respond
therapi
ten
healthi
control
also
enrol
studi
protocol
approv
institut
review
board
integri
baptist
medic
center
patient
provid
written
inform
consent
prior
enrol
treatment
protocol
patient
receiv
standard
treatment
base
weight
dose
includ
dose
gkgweek
pegyl
weight
dose
mgkg
ribavirin
patient
diagnos
hepat
c
genotyp
receiv
combin
treatment
week
wherea
patient
diagnos
genotyp
receiv
treatment
week
routin
blood
biochem
histolog
test
perform
regularli
durat
treatment
sampl
collect
process
hcv
genotyp
evalu
sera
subject
genotyp
determin
taqman
revers
transcriptionpolymeras
chain
reaction
rtpcr
tma
transcriptionmedi
amplif
use
typespecif
primer
quest
diagnost
teterboro
nj
classifi
accord
criteria
simmond
colleagu
venou
whole
blood
hepat
c
patient
collect
patient
prior
month
follow
ribavirin
therapi
blood
collect
endotoxinfre
siliconeco
tube
without
addit
blood
sampl
allow
clot
room
temperatur
min
centrifug
rpm
c
min
serum
remov
store
c
analyz
multiplex
cytokin
assay
multiplex
biometr
enzymelink
immunosorb
assay
elisa
base
immunoassay
contain
dy
microspher
conjug
monoclon
antibodi
specif
target
protein
use
accord
manufactur
instruct
bioplex
human
cytokin
assay
biorad
inc
hercul
ca
cytokin
measur
granulocyt
coloni
stimul
factor
gcsf
granulocytemonocyt
coloni
stimul
factor
gmcsf
monocyt
chemoattract
protein
mcp
macrophag
inflammatori
protein
mip
briefli
serum
sampl
dilut
incub
antibodycoupl
bead
complex
wash
incub
biotinyl
detect
antibodi
final
streptavidinphycoerythrin
prior
assess
cytokin
concentr
titer
concentr
human
recombin
cytokin
provid
vendor
biorad
inc
broad
rang
pgml
standard
use
establish
standard
curv
maxim
sensit
dynam
rang
assay
cytokin
level
determin
use
bioplex
array
reader
autom
flowbas
microfluid
devic
use
duallas
fluoresc
detector
realtim
digit
signal
process
quantit
luminex
austin
tx
instrument
quantit
multiplex
immunoassay
format
small
fluid
volum
concentr
analyt
assay
calcul
use
standard
curv
softwar
provid
manufactur
regress
analysi
perform
deriv
equat
use
predict
concentr
cytokin
serum
sampl
statis
analysi
patient
cluster
three
group
low
moder
highrespons
group
base
similar
quantit
chang
viral
titer
month
use
student
ttest
measur
signific
chang
viral
titer
calcul
pretreat
viral
titer
viral
titer
month
nonparametr
variabl
analyz
use
mannwhitney
u
test
p
valu
consid
statist
signific
correl
cluster
use
determin
common
among
particip
profil
cluster
determin
use
analysi
method
base
pearson
correl
entail
determin
paramet
term
connect
profil
connect
equal
number
screen
particip
whose
cytokin
express
level
chang
respect
time
correl
observ
individu
appropri
threshold
correl
coeffici
use
defin
connect
calcul
use
simul
studi
type
error
minim
cytokin
profil
consid
correl
among
individu
pearson
correl
coeffici
deriv
comparison
valu
use
formula
entir
data
set
sort
connect
cluster
process
start
patient
highest
connect
patient
compris
cluster
next
set
patient
higher
connect
belong
first
cluster
patient
correl
compris
cluster
process
continu
particip
dataset
analyz
cluster
resort
connect
within
cluster
mosaic
represent
correl
coeffici
graph
use
sigmaplot
spss
inc
chicago
il
hcv
genotyp
rna
titer
studi
cohort
adult
patient
men
women
mean
age
confid
interv
ci
chronic
hepat
c
infect
follow
prospect
treatment
combin
pegyl
ribavirin
liver
biopsi
peripher
blood
sampl
obtain
prior
therapi
blood
sampl
collect
month
follow
therapi
viral
test
assess
clinic
paramet
tabl
viral
subtyp
demonstr
four
differ
hcv
subtyp
present
within
cohort
subtyp
viral
titer
peripher
blood
sampl
estim
quantit
pcr
viral
titer
decreas
patient
month
combin
therapi
highlight
efficaci
treatment
modal
tabl
figur
titer
drop
detect
level
four
patient
depict
complet
remiss
remain
patient
respons
therapi
variabl
tabl
figur
end
treatment
eot
patient
viral
neg
patient
lost
followup
svr
determin
eight
patient
seven
remain
viral
neg
one
relaps
tabl
refin
understand
heterogen
therapeut
respons
patient
classifi
three
statist
distinct
group
base
quantit
chang
viral
titer
month
posttreat
group
use
analysi
three
distinct
group
denot
highrespons
group
group
c
includ
four
patient
moderaterespons
group
group
b
also
includ
four
patient
lowrespons
group
group
includ
two
patient
figur
though
viral
titer
drop
detect
level
one
patient
patient
includ
group
c
due
fact
pretreat
viral
titer
valu
patient
low
lowest
cohort
overal
chang
viral
titer
month
high
individu
group
c
also
note
individu
highrespons
group
undetect
level
viru
month
common
highest
quantit
drop
viral
titer
month
declin
viral
titer
group
c
significantli
higher
group
b
p
p
declin
viral
titer
group
b
significantli
higher
group
p
multiplex
serum
cytokin
assay
hcv
treatment
modul
immun
respons
host
heterogen
therapeut
respons
may
therefor
due
differ
host
respons
viru
therapi
combin
two
inflamm
immun
mediat
part
action
cytokin
use
multiplex
cytokin
immunoassay
assess
therapyinduc
chang
overal
host
respons
patient
broadspectrum
cytokin
panel
includ
mediat
humor
cellmedi
immun
inflamm
therebi
provid
mean
discern
gross
subtl
differ
inflammatori
immunolog
state
individu
cohort
serum
cytokin
level
assess
patient
prior
initi
therapi
denot
baselin
level
intrigu
aspect
data
provid
evid
one
patient
like
experienc
dramat
inflammatori
episod
prior
treatment
major
cytokin
individu
includ
gcsf
gmcsf
substanti
increas
cytokin
level
two
order
magnitud
higher
level
observ
remain
patient
figur
hcv
titer
drop
detect
level
patient
month
therapi
cytokin
level
increas
suggest
inflammatori
respons
patient
due
directli
hcv
infect
moreov
cytokin
level
high
patient
prior
therapi
suggest
respons
due
reaction
ribavirin
treatment
cytokin
level
remain
extrem
high
patient
month
figur
may
indic
unrel
chronic
infect
autoimmun
diseas
hcvinduc
rheumat
diseas
interestingli
patient
experienc
arthralgia
myalgia
cytokin
level
characterist
patient
inflammatori
arthriti
prior
treatment
suggest
patient
may
also
preexist
musculoskelet
diseas
therefor
assess
level
sever
biochem
marker
autoimmun
serum
level
rheumatoid
factor
rf
anticycl
citrulin
peptid
antibodi
diagnost
marker
rheumatoid
arthriti
antinuclear
antibodi
diagnost
marker
system
lupu
erythematosu
syndrom
polymyos
scleroderma
creactiv
protein
crp
inflammatori
marker
assess
prior
post
therapi
marker
rf
crp
elev
normal
level
patient
may
also
occur
hcv
infect
given
uniqu
cytokin
respons
patient
exclud
analysi
remain
nine
patient
overal
cytokin
level
measur
prior
therapi
rang
pgml
ci
level
significantli
higher
observ
control
popul
p
rang
pgml
ci
month
therapi
overal
serum
cytokin
level
decreas
patient
p
valu
rang
pgml
ci
suggest
assess
serum
cytokin
level
may
provid
clinic
relev
inform
regard
hcv
infect
therapeut
respons
correl
cytokin
therapeut
respons
chang
individu
serum
cytokin
level
assess
correl
level
chang
viral
titer
determin
averag
level
given
serum
cytokin
decreas
three
standard
deviat
therapi
chang
consid
statist
signific
group
c
group
signific
drop
viral
titer
decreas
observ
level
month
combin
therapi
figur
patient
moder
drop
viral
titer
respons
therapi
group
b
significantli
decreas
level
three
cytokin
gcsf
fig
weakli
respons
patient
group
decreas
significantli
posttreat
figur
cytokin
statist
signific
decreas
month
posttherapi
three
group
figur
statist
signific
elev
serum
cytokin
level
observ
group
increas
month
posttreat
figur
data
demonstr
patient
differenti
inflammatori
immun
respons
differ
correl
therapeut
respons
nine
patient
group
averag
level
cytokin
compar
found
significantli
decreas
treatment
p
figur
assess
patientbypati
basi
chang
level
significantli
correl
decreas
viral
titer
nine
patient
decreas
serum
level
observ
month
therapi
high
moder
respond
remain
unchang
increas
patient
weakest
respons
therapi
group
specif
patient
correl
cluster
clear
correl
establish
cytokin
level
therapeut
respons
assess
potenti
multiplex
cytokin
monitor
defin
like
therapeut
respons
multivari
analyt
method
correl
cluster
use
group
patient
similar
chang
cytokin
level
month
therapi
result
analys
repres
graphic
output
denot
cluster
mosaic
use
assess
result
visual
inspect
base
cytokin
chang
three
distinct
cluster
patient
obtain
interestingli
patient
strong
moder
respons
therapi
ie
signific
drop
viral
titer
cluster
one
group
two
patient
weakest
respons
therapi
cluster
separ
two
minor
cluster
figur
demonstr
expect
result
therapeut
respons
characterist
effect
system
cytokin
level
therefor
immuneinflammatori
respons
introduct
new
agent
regimen
treatment
chronic
hepat
c
pegyl
ifn
combin
therapi
ribavirin
result
substanti
improv
svr
rate
howev
treatment
remain
challeng
particularli
certain
patient
popul
sever
virusrel
individu
patientrel
factor
associ
poor
therapeut
respons
ten
adult
patient
hcv
infect
follow
prospect
week
combin
therapi
pegyl
ifn
ribavirin
signific
chang
viral
titer
observ
major
patient
month
treatment
viru
detect
patient
greater
decreas
viral
titer
observ
remain
patient
illustr
signific
phase
therapi
regard
modul
infect
interestingli
five
six
partial
respons
patient
infect
genotyp
hcv
confirm
previou
find
lower
respons
rate
patient
viral
genotyp
demonstr
complex
therapeut
outcom
importantli
cirrhosi
project
occur
patient
chronic
infect
persist
defin
base
nonrespons
therefor
crucial
defin
efficaci
treatment
host
respons
play
key
role
respons
viru
express
biolog
function
cytokin
therefor
critic
defin
host
respons
mediat
princip
regul
immun
respons
assess
role
host
respons
therapeut
outcom
use
multiplex
cytokin
immunoassay
measur
therapyinduc
chang
among
serum
cytokin
cohort
serum
cytokin
level
assess
patient
prior
initi
therapi
posttherapi
distinct
set
cytokin
characterist
autoimmun
diseas
grossli
upregul
one
patient
rel
individu
cohort
remain
high
despit
absenc
detect
viru
month
therapi
hcv
shown
potenti
induc
autoimmun
diseas
includ
inflammatori
arthriti
syndrom
rel
high
cytokin
level
persist
signific
arthralg
myalgic
symptom
absenc
detect
viru
may
suggest
need
antiinflammatori
therapi
patient
diagnost
biochem
analys
fail
identifi
like
caus
musculoskelet
symptom
serum
cytokin
profil
provid
like
biochem
basi
evid
system
inflammatori
symptom
demonstr
util
cytokin
profil
screen
tool
remain
nine
patient
serum
cytokin
level
measur
prior
therapi
significantli
higher
observ
control
popul
p
month
therapi
overal
serum
cytokin
level
decreas
patient
p
group
c
group
signific
drop
viral
titer
highrespons
group
signific
decreas
observ
level
month
combin
therapi
patient
moder
drop
viral
titer
respons
therapi
group
b
significantli
decreas
level
three
cytokin
gcsf
weakli
respons
patient
group
significantli
decreas
posttreat
therefor
demonstr
patient
differenti
immun
respons
differ
categor
correl
therapeut
respons
use
correl
cluster
three
distinct
cluster
patient
obtain
intriguingli
cluster
correl
well
viral
titer
data
largest
cluster
strong
moder
respond
contain
patient
group
b
c
group
patient
weak
respond
present
two
separ
minor
cluster
result
demonstr
serum
cytokin
level
effect
use
distinguish
weak
respond
moder
strong
respond
data
also
suggest
heterogen
therapeut
respons
part
mediat
differ
host
respons
among
individu
cohort
found
significantli
decreas
cytokin
posttreat
patient
group
togeth
chang
level
significantli
correl
decreas
viral
titer
nine
patient
data
assess
patientbypati
basi
decreas
serum
level
observ
month
therapi
high
moder
respond
howev
serum
level
remain
unchang
increas
patient
weakest
respons
therapi
group
specif
patient
associ
drop
level
month
respons
viru
month
may
prognost
merit
drop
level
month
also
correl
respons
end
treatment
svr
liverinfiltr
cell
express
high
level
receptor
rant
ligand
constitut
express
portal
vessel
provid
mechan
recruit
memori
cell
portal
area
normal
liver
immun
surveil
well
recruit
cell
portal
area
inflammatori
liver
diseas
preferenti
activ
lymphocyt
trigger
activ
furthermor
liver
injuri
mediat
cell
graftversushost
diseas
decreas
serum
level
posttreat
suggest
decreas
transendotheli
migrat
leukocyt
occur
respons
patient
would
preclud
retent
surviv
lymphocyt
liver
therebi
amelior
tissu
damag
fibrosi
accordingli
concomit
decreas
cytokin
ere
observ
patient
highest
respons
rate
would
expect
given
predominantli
immun
respons
liver
hcv
patient
intracellular
immun
influenc
imper
defens
viral
infect
mediat
cell
infiltr
essenti
deliveri
mediat
downstream
protect
respons
hcv
infect
liver
shown
recent
intrahepat
gene
express
profil
chimpanze
upregul
acut
infect
time
viral
clearanc
fail
erad
viru
previou
studi
demonstr
hcvinfect
individu
diminish
respons
liver
data
fact
serum
level
correl
therapeut
respons
nine
patient
suggest
action
part
influenc
appropri
treatmentinduc
host
respons
hcv
also
interest
note
correl
level
therapeut
efficaci
also
consist
oppos
hypothes
chronic
mediat
inflamm
limit
effect
antivir
therapi
prime
contributor
morbid
induc
liver
damag
somewhat
antithet
conjectur
consist
recent
observ
mortal
sar
viru
infect
due
part
inflamm
induc
lung
viru
fact
mortal
decreas
treat
sar
patient
combin
cours
immunosuppress
corticosteroid
antivir
ribavirin
late
infect
cycl
time
host
respons
caus
maxim
damag
infect
tissu
provoc
hypothes
valid
treat
nonrespons
hcv
patient
combin
immunosuppress
antivir
may
improv
respons
rate
target
therapi
could
interest
futur
clinic
trial
defect
abil
mount
appropri
cellular
immun
respons
respons
establish
chronic
hcv
infect
mechan
regul
induct
integr
cellular
humor
respons
chronic
hcv
fulli
elucid
cytokin
shown
herein
effect
noninvas
marker
sustain
respons
potenti
prognost
surrog
therapeut
outcom
assess
cytokin
profil
contain
chemotact
humor
inflammatori
cytokin
help
elucid
pathogen
process
individu
basi
may
help
understand
natur
immun
process
hcv
patient
overal
therebi
assist
prognost
treatment
decis
